HLA Correlations with Clinical Phenotypes and Risk of Metabolic Comorbidities in Singapore Chinese Psoriasis Patients
- 48 Downloads
Psoriasis is a systemic, chronic inflammatory disease that not only afflicts the skin but is also associated with cardiovascular disease and metabolic syndrome. The strongest susceptibility loci for the disease is within the human leukocyte antigen (HLA) complex, though specific HLA allelic associations vary between populations.
Our objective was to investigate HLA associations with clinical phenotypes of psoriasis and metabolic syndrome in Chinese psoriasis cases.
We conducted an observational case–control study in Singapore with a cohort of psoriasis cases consecutively recruited from an outpatient specialist dermatological center (n = 120) compared with 130 healthy controls.
Significant HLA associations with psoriasis were observed with HLA-A*02:07, B*46:01, C*01:02, and C*06:02. The three-locus haplotype of A*02:07-C*01:02-B*46:01 was also significant (odds ratio [OR] 3.07; p = 9.47 × 10−5). We also observed an association between nail psoriasis and HLA-A*02:07 carriers (OR 4.50; p = 0.002), whereas C*06:02 carriers were less prone to have nail involvement (OR 0.16; p = 0.004). HLA-A*02:07 was also identified as a possible risk allele for hypertension (OR 2.90; p < 0.05), and C*01:02 was a possible risk allele for dyslipidemia (OR 3.36; p < 0.05), both known to be common comorbidities in patients with psoriasis.
Our results demonstrate the growing importance of discerning population-specific clinical phenotypes and their association with certain HLA alleles in psoriasis.
The authors are grateful for the support of research coordinators from the National Skin Centre: Jie Si Kwa, Yan Qin Mak, Umairah Adnan, Joan Fung and Veron Lu.
Compliance with Ethical Standards
Conflict of interest
MS, SWDL, EST, HHO, and ECR have no conflicts of interest that are directly relevant to the content of this article.
This study was funded by Singapore Immunology Network F00006 core fund.
Ethical approval and informed consent
This clinical study was approved by the IRB on “Genetic susceptibility in psoriasis with psoriatic arthritis and metabolic syndrome” (IRB number 2014/01132) and conducted according to the principles of the Declaration of Helsinki.
- 12.Guðjónsson JE, Valdimarsson H, Kárason A, Antonsdóttir AA, Hjaltey Rúnarsdóttir E, Gulcher JR, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002;118:362–5.Google Scholar
- 17.Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital di Dermatologia e Venereol. 2016;151:663–77.Google Scholar
- 21.Dormoy A, Froelich N, Leisenbach R, Weschler B, Cazenave J-P, Tongio M-M. Mono-allelic amplification of exons 2-4 using allele group-specific primers for sequence-based typing (SBT) of the HLA-A, -B and -C genes: preparation and validation of ready-to-use pre-SBT mini-kits. Tissue Antigens. 2003;62:201–16.PubMedGoogle Scholar
- 24.Zhang X, Wei S, Yang S, Wang Z, Zhang A, He P, et al. HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han. Int J Dermatol. England. 2004;43:181–7.Google Scholar